In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
 Frans Van de Werf
Speaker
Frans Van de Werf

University of Leuven, Leuven (Belgium)

Specialities : Acute Coronary Syndromes , Risk Factors and Prevention

I very much enjoyed my membership of the Board of the ESC during many years. It gives me great satisfaction to see the ESC as a leading professional organization

Dr Frans Van de Werf gained his MD in 1972 from the University of Leuven, Belgium. He has made his PhD on diastolic heart function and the genesis of the third heart sound. He was the first to give tPA to patients with an acute myocardial infarction and became involved in the organization of many multicentre trials of antithrombotic therapy in acute coronary syndromes. He has published over 700 peer reviewed papers. Dr Van de Werf is currently Senior Professor of Cardiology at the department of cardiovascular sciences of the University of Leuven.

20 presentations from this speaker

Welcome and introduction

Congress : ESC Congress 2019

  • Session : STEMI care today: can we do better?
  • Speaker : F Van de Werf (Leuven,BE)
  • Sponsored by Boehringer Ingelheim

Introduction from the chairs.

Congress : ESC Congress 2017

  • Session : Challenges and opportunities of establishing reperfusion networks for ST-segment elevation myocardial infarction (STEMI) and for acute stroke
  • Speaker : F Van de Werf (Leuven,BE)
  • Sponsored by Boehringer Ingelheim International GmbH

Networks and reperfusion strategies for STEMI and ischaemic stroke: interactive discussion session.

Congress : ESC Congress 2017

  • Session : Challenges and opportunities of establishing reperfusion networks for ST-segment elevation myocardial infarction (STEMI) and for acute stroke
  • Speaker : P Goldstein (Lille Cedex,FR), R Welsh (Edmonton,CA), C Molina (Barcelona,ES), P R Sinnaeve (Leuven,BE), D Leys (Lille,FR), PW Armstrong (Edmonton,CA), F Van de Werf (Leuven,BE)
  • Sponsored by Boehringer Ingelheim International GmbH

Lipids lowering in diabetics. What is the best way?

Congress : ESC Congress 2016

  • Session : Improving secondary prevention of atherosclerotic disease
  • Speaker : F Van de Werf (Leuven,BE)
  • Joint with the International Society of Cardiovascular Pharmacotherapy

Acute coronary syndromes

Congress : ESC Congress 2015

  • Session : The European Heart Journal`s year in cardiology: from prevention to intervention
  • Speaker : F Van de Werf (Leuven,BE)

Keynote lecture: "The history of the fight against coronary thrombosis".

Congress : Acute Cardiovascular Care 2015

  • Session : Inaugural Session
  • Speaker : F Van de Werf (Leuven,BE)

Trial Evaluating Cardiovascular Outcomes with Sitagliptin in patients with type-2 Diabetes.

Congress : ESC Congress 2015

  • Session : Meet the Trialist III: TECOS
  • Speaker : F Van de Werf (Leuven,BE)

Trial Evaluating Cardiovascular Outcomes with Sitagliptin in patients with type-2 Diabetes: TECOS

Congress : ESC Congress 2015

  • Session : Hot Line III - Diabetes mellitus/Pharmacology
  • Speaker : F Van de Werf (Leuven,BE)

Discrimination of risk profiles in clinical practice.

Congress : ESC Congress 2014

  • Session : Prevention of atherothrombotic event episodes: can we do better?
  • Speaker : F Van de Werf (Leuven,BE)
  • Sponsored by MSD

ISCHEMIA.

Congress : ESC Congress 2014

  • Session : Strategy trials: important or impossible?
  • Speaker : F Van de Werf (Leuven,BE)

Panel discussion: pharmaco-invasive vs. primary PCI.

Congress : ESC Congress 2014

  • Session : STEMI 2014: aligning optimal care to time, place and person
  • Speaker : N Danchin (Montreuil,FR), PW Armstrong (Edmonton,CA), F Van de Werf (Leuven,BE), K Huber (Vienna,AT), Y Lambert (Le Chesnay,FR), A Galyavich (Kazan,RU)
  • Sponsored by Boehringer Ingelheim

Should the STEMI guidelines be updated?

Congress : ESC Congress 2014

  • Session : STEMI 2014: aligning optimal care to time, place and person
  • Speaker : F Van de Werf (Leuven,BE)
  • Sponsored by Boehringer Ingelheim

Summary and close - Antiplatelet therapy in high-risk patients with ACS.

Congress : ESC Congress 2014

  • Session : Antiplatelet therapy in high-risk patients with acute coronary syndromes - Current evidence and future directions
  • Speaker : F Van de Werf (Leuven,BE)
  • Organised by The Sahlgrenska Academy - Goteborg University / Course Director: Karl Swedberg / Supported by an unrestricted educational grant from AstraZeneca

What are the conclusions from CardioScape?

Congress : ESC Congress 2014

  • Session : Surveying the European cardiovascular research landscape: results from CardioScape
  • Speaker : F Van de Werf (Leuven,BE)

Evolving evidence: bridging the gaps among clinical trials, registries, and clinical practice.

Congress : ESC Congress 2013

  • Session : Antiplatelet therapy in acute coronary syndromes: translating evidence into clinical practice to improve outcomes
  • Speaker : F Van de Werf (Leuven,BE)
  • Organised by The Sahlgrenska Academy - University of Gothenburg / Course Director: Prof. Karl Swedberg / Supported by an unrestricted educational grant from AstraZeneca

Panel and audience discussion: perception of STREAM from the outside world.

Congress : ESC Congress 2013

  • Session : STREAM-lining STEMI patients for timely reperfusion
  • Speaker : F Van de Werf (Leuven,BE)
  • Sponsored by Boehringer Ingelheim

Pharmaco-invasive strategy compared with PPCI: design and main outcomes of the STREAM trial.

Congress : ESC Congress 2013

  • Session : STREAM-lining STEMI patients for timely reperfusion
  • Speaker : F Van de Werf (Leuven,BE)
  • Sponsored by Boehringer Ingelheim

RE-ALIGN: Dabigatran in patients with a mechanical heart valve

Congress : ESC Congress 2013

  • Session : Hot Line I: Late Breaking Trials on Thrombosis
  • Speaker : F Van de Werf (Leuven,BE)

The history of coronary reperfusion in STEMI.

Congress : ESC Congress 2013

  • Session : Meet the Legends: Frans Van de Werf
  • Speaker : F Van de Werf (Leuven,BE)

The top ten most promising therapies in cardiovascular medicine.

Congress : ESC Congress 2013

  • Session : The milestones in cardiovascular medicine - the past and the future
  • Speaker : F Van de Werf (Leuven,BE)

Three reasons why you should become a member

Become a member now
  • 1Access your congress resources all year-round on the New ESC 365
  • 2Get a discount on your next congress registration
  • 3Continue your professional development with free access to educational tools
Become a member now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are